Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 8935 results

  1. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development Reference number: GID-TA11221 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  11 August 2026

    Health technology evaluations
    In development

  3. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    In development Reference number: GID-TA11818 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development Reference number: GID-TA11501 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    In development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]

    Awaiting development Reference number: GID-TA11914 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]

    Awaiting development Reference number: GID-TA11916 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Tirzepatide for managing overweight and obesity in people 12 to 17 years [TSID12322]

    Awaiting development Reference number: GID-TA11923 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Suspected sepsis in pregnancy: recognition, diagnosis and early management

    In development Reference number: GID-NG10468 Expected publication date:  17 February 2027

    NICE guideline
    In development

  10. Xanomeline tartrate–trospium chloride for treating schizophrenia [TSID12311]

    Awaiting development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  12. Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  14. Asunercept for treating glioblastoma [ID1301]

    In development Reference number: GID-TA10227 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]

    In development Reference number: GID-TA11636 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development